Triavera Capital LLC Purchases 2,525 Shares of Danaher Corporation $DHR

Triavera Capital LLC grew its position in Danaher Corporation (NYSE:DHR) by 10.8% during the second quarter, Holdings Channel reports. The institutional investor owned 25,946 shares of the conglomerate’s stock after acquiring an additional 2,525 shares during the quarter. Danaher comprises 2.7% of Triavera Capital LLC’s investment portfolio, making the stock its 18th largest holding. Triavera Capital LLC’s holdings in Danaher were worth $5,125,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Argyle Capital Partners LLC boosted its stake in Danaher by 36.6% in the second quarter. Argyle Capital Partners LLC now owns 5,598 shares of the conglomerate’s stock valued at $1,106,000 after acquiring an additional 1,500 shares in the last quarter. Peloton Wealth Strategists lifted its holdings in shares of Danaher by 2.9% during the 2nd quarter. Peloton Wealth Strategists now owns 5,741 shares of the conglomerate’s stock valued at $1,134,000 after purchasing an additional 160 shares during the last quarter. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of Danaher during the 2nd quarter valued at $51,000. Groupe la Francaise boosted its position in shares of Danaher by 363.2% in the 2nd quarter. Groupe la Francaise now owns 120,835 shares of the conglomerate’s stock worth $23,786,000 after purchasing an additional 94,750 shares in the last quarter. Finally, Blueshift Asset Management LLC purchased a new position in Danaher during the 2nd quarter worth $333,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $226.82 on Wednesday. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The company has a market cap of $160.21 billion, a PE ratio of 46.77, a price-to-earnings-growth ratio of 4.35 and a beta of 0.89. The company’s 50 day moving average is $213.63 and its 200 day moving average is $203.77.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period in the prior year, the firm earned $1.71 EPS. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Robert W. Baird set a $247.00 price objective on shares of Danaher in a report on Wednesday, October 22nd. Rothschild & Co Redburn reiterated a “neutral” rating and issued a $220.00 target price (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. HSBC boosted their target price on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday. Finally, JPMorgan Chase & Co. raised their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Twenty investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $245.75.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Teri List sold 3,298 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares of the company’s stock, valued at $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 30,248 shares of company stock worth $6,609,663. Insiders own 11.20% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.